Could a pill help patients breathe easier with ARDS?

NCT ID NCT07086755

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called vadadustat in 1,100 hospitalized adults with acute respiratory distress syndrome (ARDS) caused by infection. Participants take either a low or high dose of vadadustat or a placebo daily for up to 14 days. The goal is to see if the drug reduces deaths and the need for breathing support like ventilators.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vadadustat (oral tablet)

What this could lead to

If it works, this could provide a new treatment to reduce deaths and shorten the need for breathing machines in patients with severe lung injury.

What could go wrong

This is an early-to-mid stage trial, so results may not confirm benefit. The drug may cause side effects or not improve outcomes compared to placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONINTUBATED ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas Health Science Center at Houston

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact